'Podnosis': Biosimilars' potential to curtail drug prices and what to do about rural communities' healthcare access crisis
07 Dec 2022
Preview
Source: FierceHealthcare
Nearly 80% of rural counties are short on primary care doctors, and 9% have none at all.
The healthcare industry is grappling with rising drug prices. The expectation is, though, that the wave of biosimilars launching next year will make a dent in healthcare costs. Paige Minemyer interviews Alan Lotvin, M.D., president of CVS Health’s Caremark pharmacy benefit manager, about biosimilars’ potential.
Also in the episode, Heather Landi talks to Jennifer Schneider, M.D., about how rural communities are facing a healthcare access crisis and what can be done about it. Schneider is the CEO of Homeward, a technology-enabled healthcare provider delivering care to rural America.
To learn more about topics in this episode:
CVS: Specialty drugs accounted for 52% of pharmacy spend in 2020
How CVS Caremark kept specialty drug trend to an industry low in 2021
Industry Voices—Leveraging biosimilars for lower specialty drug costs
Rural America is fertile ground for healthcare innovation, experimentation, tech leaders say
Startup Homeward inks partnership with Rite Aid to provide primary care in rural communities
Launched just 5 months ago, Homeward clinches $50M, inks major Medicare Advantage partnership
GAO: Fewer providers in rural, underserved areas join advanced alternative payment models
Podnosis is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Heather Landi and Paige Minemyer. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.